Kalaris Therapeutics Inc (KLRS) Stock Analysis & Investment Frameworks
Kalaris Therapeutics Inc (KLRS) stock analysis on Invetso. Review Kalaris Therapeutics Inc’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Kalaris Therapeutics Inc Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Kalaris Therapeutics Inc Key Financial Metrics
- Market Cap: $45.21M
- Revenue: $N/A
- ROE: -71.71%
- ROIC: -52.40%
- Dividend Yield: N/A
About Kalaris Therapeutics Inc
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
Kalaris Therapeutics Inc Investment Frameworks
Invetso analyzes Kalaris Therapeutics Inc (KLRS) across the following frameworks:
- Kalaris Therapeutics Inc 10Y Growth Potential
- Kalaris Therapeutics Inc Scenario Analysis
- Kalaris Therapeutics Inc Risks & Opportunities
- Kalaris Therapeutics Inc Economic Moat
- Kalaris Therapeutics Inc Business Model
- Kalaris Therapeutics Inc Management
- Kalaris Therapeutics Inc SWOT Analysis
- Kalaris Therapeutics Inc Porter's 5 Forces
- Kalaris Therapeutics Inc PESTLE Analysis
- Kalaris Therapeutics Inc ESG Analysis